Literature DB >> 33748161

C3AR1 mRNA as a Potential Therapeutic Target Associates With Clinical Outcomes and Tumor Microenvironment in Osteosarcoma.

Tiannan Zou1,2,3, Weibing Liu1, Zeyu Wang1,3, Jiayu Chen1,3, Sheng Lu1,2,3, Kun Huang1,3, Weichao Li1,2,3.   

Abstract

Objective: Targeting cancer-specific messenger RNAs (mRNAs) may offer novel insights into therapeutic strategies in osteosarcoma. This study aimed to discover possible osteosarcoma-specific mRNA and probe its biological functions.
Methods: Based on mRNA-seq data from the TARGET database, stromal and immune scores were estimated for each osteosarcoma sample via the ESTIMATE algorithm. Stromal and immune mRNAs were obtained via integration of differentially expressed mRNAs between high and low stromal / immune score groups. Among hub and prognostic mRNAs, C3AR1 mRNA was focused and its prognostic value was assessed. The associations between C3AR1 mRNA and immune cells were analyzed via the CIBERSORT algorithm. Its expression was verified in osteosarcoma tissues and cells by RT-qPCR and western blot. The functions of C3AR1 were investigated by a series of experiments.
Results: Low stromal and immune scores were both indicative of unfavorable outcomes for osteosarcoma patients. Eighty-eight up-regulated and seven down-regulated stromal and immune mRNAs were identified. Among 30 hub mRNAs, low expression of C3AR1 mRNA indicated worse outcomes than its high expression. There was a lower mRNA expression of C3AR1 in metastatic than non-metastatic osteosarcoma. C3AR1 mRNA was closely correlated to various immune cells such as macrophages. C3AR1 was verified to be down-regulated in osteosarcoma tissues and cells. Its overexpression suppressed proliferation, migration and invasion and induced apoptosis in osteosarcoma cells.
Conclusion: C3AR1 mRNA could be a promising therapeutic target for osteosarcoma, linked with prognosis and tumor microenvironment.
Copyright © 2021 Zou, Liu, Wang, Chen, Lu, Huang and Li.

Entities:  

Keywords:  C3AR1; mRNA; osteosarcoma; prognosis; therapeutic target; tumor immune microenvironment

Year:  2021        PMID: 33748161      PMCID: PMC7973027          DOI: 10.3389/fmed.2021.642615

Source DB:  PubMed          Journal:  Front Med (Lausanne)        ISSN: 2296-858X


  5 in total

1.  Inhibitory effect of CUL1 on atherosclerosis through the p53 pathway.

Authors:  Xi Zhang; Youwei Lu; Wei Jiang; Qianhong Yang
Journal:  Ann Transl Med       Date:  2022-09

2.  Construction and validation of a novel apoptosis-associated prognostic signature related to osteosarcoma metastasis and immune infiltration.

Authors:  Yucheng Fu; Zhijian Jin; Yuhui Shen; Zhusheng Zhang; Meng Li; Zhuochao Liu; Guoyu He; Jintao Wu; Junxiang Wen; Qiyuan Bao; Jun Wang; Weibin Zhang
Journal:  Transl Oncol       Date:  2022-05-19       Impact factor: 4.803

3.  Identification and Validation of Immune-Related Gene for Predicting Prognosis and Therapeutic Response in Ovarian Cancer.

Authors:  Zhao-Cong Zhang; Jun-Nan Guo; Ning Zhang; Zhi-Qiang Wang; Ge Lou; Bin-Bin Cui; Chang Yang
Journal:  Front Immunol       Date:  2021-11-22       Impact factor: 7.561

4.  Bioinformatics analysis of lncRNAs in the occurrence and development of osteosarcoma.

Authors:  Hua Liu; Chenyu Zong; Jiacheng Sun; Haiyang Li; Guangzhen Qin; Xiaojian Wang; Jianwei Zhu; Yang Yang; Qiang Xue; Xianchen Liu
Journal:  Transl Pediatr       Date:  2022-07

5.  Single-Cell RNA-Sequencing Reveals the Active Involvement of Macrophage Polarizations in Pulmonary Hypertension.

Authors:  Xulong Mao; Yaozhe Li; Rui Yang; Jingqiu Wei; Zhucheng Zhao; Ting Zhang; Mingli OuYang; Xiaoling Liu; Can Liu; Hao Xu; Xiaoying Huang; Liangxing Wang
Journal:  Dis Markers       Date:  2022-08-26       Impact factor: 3.464

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.